PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.
Some users of RU-58841 report cardiovascular symptoms like heart palpitations and chest tightness, which may be linked to its metabolites causing lung disease. The safety of RU-58841 is uncertain due to lack of long-term data and concerns about product purity, especially from gray market sources.
A user's 2 year experience using Minoxidil and Finasteride combined with 20,000mcg of biotin daily and dermarolling for 1 year. The results included thicker hair with some regrowth closer to the hairline, although peak results have not been achieved yet.
Hair loss discussion mentions using estrogen mixed with growth stimulants like oral minoxidil for scalp hair growth. Idea proposed for an artificial SARM-estrogen that only affects hair without body side effects.
User "Ant1pal" shares progress pictures of hair regrowth using Minoxidil, Estradiol valerate, and Spironolactone. Users discuss potential side effects and the possibility of localizing estrogen to hair follicles for better treatment.
Hair loss theory involves 3alpha-hydroxysteroid reductase (3AHD) converting DHT to androstenol. Discussion explores potential treatments and encourages more research.
Switching to dutasteride as a hair loss prevention treatment, along with minoxidil, dermarolling and nizoral shampoo, and the potential benefits and side effects of using finasteride and/or dutasteride in combination with topical anti-androgens like RU58841.